In vitro hemolysis: guidance for the pharmaceutical scientist
Ketan Amin1, Rose-Marie Dannenfelser
1Johnson & Johnson Co., Global Pharmaceutical Supply Group, 1150 Route 22 East, Bridgewater, NJ 08807, USA. kamin1@gpsus.jnj.com
Journal of Pharmaceutical Sciences
|April 28, 2006
Summary
This study evaluates the hemolytic potential of parenteral formulation excipients using in vitro hemolysis assays. Results provide guidance for selecting nonhemolytic excipients in drug development to ensure patient safety.
Area of Science:
- Pharmaceutical Sciences
- Biocompatibility Testing
- Drug Delivery Systems
Background:
- Pharmaceutical excipients are crucial for parenteral formulation solubility and stability.
- Excipient biocompatibility, particularly hemolytic potential, is vital for parenteral products.
- Existing literature on excipient hemolytic potential contains conflicting information.
Purpose of the Study:
- To compare the hemolytic potential of common parenteral formulation vehicles.
- To provide clear guidance on excipient selection based on hemolysis risk.
- To address contradictory information regarding excipient hemolytic activity.
Main Methods:
- In vitro hemolysis assay using dog, rabbit, and human blood.
- Evaluation of various formulation vehicles found in marketed drug products.
- Classification of hemolysis values: <10% nonhemolytic, >25% at risk.
Main Results:
- Hemolytic potential varied significantly among different formulation vehicles.
- Specific excipients demonstrated distinct hemolytic profiles across species.
- Established clear thresholds for defining nonhemolytic and potentially hemolytic formulations.
Conclusions:
- The study clarifies the hemolytic potential of key parenteral excipients.
- Provides a framework for risk assessment in parenteral formulation development.
- Aims to improve the safety and efficacy of parenteral drug products through informed excipient selection.
